Evaluation of Diagnostic Value of 3-T Magnetic Resonance Imaging (MRI) in Suspected Prostate Cancer

University of Oulu130 enrolled

Overview

The purpose of the study is to evaluate the usefulness of 3-T magnetic resonance imaging (MRI) in the evaluation of suspected prostate cancer. Men with suspected prostate cancer based on serum prostate-specific antigen antigen (PSA) value are included. Men are randomized to pre-biopsy MRI or no MRI groups in ratio 1:1. Standard transrectal ultrasound guided biopsies will be taken in addition to extra biopsies from lesions suspicious based on MRI evaluation. Hypothesis is that more prostate cancers will be found after MRI evaluation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

130

Conditions

Prostatic Neoplasms

Interventions

magnetic resonance imaging, SiemensDEVICE

Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device

Eligibility

Sex: MALEMin age: 40 YearsMax age: 72 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Informed consent * Suspected prostate cancer based on PSA value (total PSA 2,5-10 ng/ml and PSA free to total ratio \<=0.15, or total PSA 10-20 ng/ml) * PSA and serum creatinine measurement less than 60 days before transrectal ultrasound-guided prostate biopsies * No evidence of PSA increase by non-cancerous factors (catheterization, bladder stones, urinary tract infection including bacterial prostatitis) Exclusion Criteria: * Previous prostate biopsies * Previous prostate surgery * Contraindication for MRI (such as pacemaker or inner ear implant) * Claustrophobia * Estimated glomerular filtration rate (eGFR) \<40 ml/min * Suspected clinical T3-T4 prostate cancer based on digital rectal examination * Contraindication for transrectal ultrasound-guided prostate biopsies * body mass index \>30

Locations (1)

Oulu University Hospital

Oulu, Finland

Outcomes

Primary Outcomes

Number of Prostate Cancer Diagnoses in MRI and no MRI Groups

The number of patients with confirmed prostate cancer among men with MRI performed before biopsies are compared to the number of patients with prostate cancer confirmed in prostate biopsies without MRI. The number patients with prostate cancer are counted as total from cancers detected in random biopsies and in biopsies targeted based on suspicious MRI findings in MRI group, and from random biopsies in no MRI group.

Time frame: at the end of the study (up to 1 year)

Secondary Outcomes

Number of Positive Biopsies in MRI and no MRI Groups

The number of biopsies with histology confirming prostate cancer are compared between MRI and no MRI groups. This measure will clarify if prostate cancer can be diagnosed more accurately, i.e. more biopsies with confirmed prostate cancer, after MRI. Ten or 12 biopsies will be taken from prostates below 30 grams, or equal or above 30 grams, respectively.

Time frame: at the end of the study (up to 1 year)

Proportion of Clinically Significant Prostate Cancers Detected in MRI and no MRI Groups

Number of clinically significant prostate cancers detected with and without MRI. Clinically significant prostate cancer is determined by the Gleason grading and be the number of cancer-positive biopsy cores.

Time frame: at the end of the study (up to 1 year)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.